The lack of specificity of PSA as well as the risk of overdiagnosis of indolent cancers, has led to the development of personalized clinical prostate cancer risk calculators, which increasingly incorporate the findings of pre‐biopsy prostate MRI. This evidence concerns the gene KLK3 and Familial prostate cancer.